After cessation of endostatin, new vessels began to grow, thereby signaling the creation of an environment supportive to tumor growth (indicated by disease progression).[28,29] Despite such conditions, there may still be a suppressive effect on the induction of a more aggressive tumor phenotype, thus contributing to the persistent OS benefit. This evidence concerns the gene COL18A1 and neoplasm.